Antithymocyte globulin induction in living donor renal transplant recipients

Final report of the TAILOR registry

A. Osama Gaber, Arthur J. Matas, Mitchell L. Henry, Daniel Brennan, R. Brian Stevens, Sandip Kapur, Jillian N. Ilsley, Kristen D. Kistler, A. Benedict Cosimi

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The Thymoglobulin Antibody Immunosuppression in Living Donor Recipients registry was established to assess clinical experience with rabbit antithymocyte globulin (rATG; Thymoglobulin) in living donor renal transplant recipients. METHODS: From 2003 to 2008, US transplant centers prospectively entered information on patients who received rATG induction. In addition to standard United Network for Organ Sharing registry data elements, information was collected regarding immunosuppression, viral prophylaxis, acute rejection, and adverse events. RESULTS: Data on 2322 patients from 49 transplant centers were enrolled and met inclusion criteria for analysis. Patient and graft survival were 99.3% and 99.0% at 6 months and 98.4% and 98.2% at 12 months as recorded in Thymoglobulin Antibody Immunosuppression in Living Donor Recipients registry and were 91.5% and 83.2% at 5 years by Kaplan-Meier estimates based on linked United Network for Organ Sharing registry records. Freedom from rejection was 93.6% through 5 years. Mean rATG cumulative dose was 5.29 mg/kg. More than one-third of patients (37.6%) were steroid-free at discharge, and nearly half of patients (48%) were steroid-free at 12 months. Before discharge, 3.2% experienced serious adverse events, with 11 events (0.005%) reported as possibly or probably related to rATG. Incidence of cytomegalovirus infection was 4.2% at 12 months, and 99.1% of patients were posttransplant lymphoproliferative disorder-free through 5 years. CONCLUSIONS: rATG induction in living donor renal transplantation is safe and associated with a low incidence of acute rejection and posttransplantation complications.

Original languageEnglish (US)
Pages (from-to)331-337
Number of pages7
JournalTransplantation
Volume94
Issue number4
DOIs
StatePublished - Aug 27 2012
Externally publishedYes

Fingerprint

Antilymphocyte Serum
Living Donors
Registries
Kidney
Immunosuppression
Steroids
Transplants
Lymphoproliferative Disorders
Information Dissemination
Antibodies
Incidence
Cytomegalovirus Infections
Kaplan-Meier Estimate
Graft Survival
Kidney Transplantation
Transplant Recipients
Rabbits
thymoglobulin

Keywords

  • Antithymocyte globulin
  • Immunosuppression
  • Live donor transplantation
  • Renal transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Antithymocyte globulin induction in living donor renal transplant recipients : Final report of the TAILOR registry. / Gaber, A. Osama; Matas, Arthur J.; Henry, Mitchell L.; Brennan, Daniel; Stevens, R. Brian; Kapur, Sandip; Ilsley, Jillian N.; Kistler, Kristen D.; Cosimi, A. Benedict.

In: Transplantation, Vol. 94, No. 4, 27.08.2012, p. 331-337.

Research output: Contribution to journalArticle

Gaber, AO, Matas, AJ, Henry, ML, Brennan, D, Stevens, RB, Kapur, S, Ilsley, JN, Kistler, KD & Cosimi, AB 2012, 'Antithymocyte globulin induction in living donor renal transplant recipients: Final report of the TAILOR registry', Transplantation, vol. 94, no. 4, pp. 331-337. https://doi.org/10.1097/TP.0b013e31825a7d1f
Gaber, A. Osama ; Matas, Arthur J. ; Henry, Mitchell L. ; Brennan, Daniel ; Stevens, R. Brian ; Kapur, Sandip ; Ilsley, Jillian N. ; Kistler, Kristen D. ; Cosimi, A. Benedict. / Antithymocyte globulin induction in living donor renal transplant recipients : Final report of the TAILOR registry. In: Transplantation. 2012 ; Vol. 94, No. 4. pp. 331-337.
@article{2ba67be1cabd4f36bfc7c6d9446eddd5,
title = "Antithymocyte globulin induction in living donor renal transplant recipients: Final report of the TAILOR registry",
abstract = "BACKGROUND: The Thymoglobulin Antibody Immunosuppression in Living Donor Recipients registry was established to assess clinical experience with rabbit antithymocyte globulin (rATG; Thymoglobulin) in living donor renal transplant recipients. METHODS: From 2003 to 2008, US transplant centers prospectively entered information on patients who received rATG induction. In addition to standard United Network for Organ Sharing registry data elements, information was collected regarding immunosuppression, viral prophylaxis, acute rejection, and adverse events. RESULTS: Data on 2322 patients from 49 transplant centers were enrolled and met inclusion criteria for analysis. Patient and graft survival were 99.3{\%} and 99.0{\%} at 6 months and 98.4{\%} and 98.2{\%} at 12 months as recorded in Thymoglobulin Antibody Immunosuppression in Living Donor Recipients registry and were 91.5{\%} and 83.2{\%} at 5 years by Kaplan-Meier estimates based on linked United Network for Organ Sharing registry records. Freedom from rejection was 93.6{\%} through 5 years. Mean rATG cumulative dose was 5.29 mg/kg. More than one-third of patients (37.6{\%}) were steroid-free at discharge, and nearly half of patients (48{\%}) were steroid-free at 12 months. Before discharge, 3.2{\%} experienced serious adverse events, with 11 events (0.005{\%}) reported as possibly or probably related to rATG. Incidence of cytomegalovirus infection was 4.2{\%} at 12 months, and 99.1{\%} of patients were posttransplant lymphoproliferative disorder-free through 5 years. CONCLUSIONS: rATG induction in living donor renal transplantation is safe and associated with a low incidence of acute rejection and posttransplantation complications.",
keywords = "Antithymocyte globulin, Immunosuppression, Live donor transplantation, Renal transplantation",
author = "Gaber, {A. Osama} and Matas, {Arthur J.} and Henry, {Mitchell L.} and Daniel Brennan and Stevens, {R. Brian} and Sandip Kapur and Ilsley, {Jillian N.} and Kistler, {Kristen D.} and Cosimi, {A. Benedict}",
year = "2012",
month = "8",
day = "27",
doi = "10.1097/TP.0b013e31825a7d1f",
language = "English (US)",
volume = "94",
pages = "331--337",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Antithymocyte globulin induction in living donor renal transplant recipients

T2 - Final report of the TAILOR registry

AU - Gaber, A. Osama

AU - Matas, Arthur J.

AU - Henry, Mitchell L.

AU - Brennan, Daniel

AU - Stevens, R. Brian

AU - Kapur, Sandip

AU - Ilsley, Jillian N.

AU - Kistler, Kristen D.

AU - Cosimi, A. Benedict

PY - 2012/8/27

Y1 - 2012/8/27

N2 - BACKGROUND: The Thymoglobulin Antibody Immunosuppression in Living Donor Recipients registry was established to assess clinical experience with rabbit antithymocyte globulin (rATG; Thymoglobulin) in living donor renal transplant recipients. METHODS: From 2003 to 2008, US transplant centers prospectively entered information on patients who received rATG induction. In addition to standard United Network for Organ Sharing registry data elements, information was collected regarding immunosuppression, viral prophylaxis, acute rejection, and adverse events. RESULTS: Data on 2322 patients from 49 transplant centers were enrolled and met inclusion criteria for analysis. Patient and graft survival were 99.3% and 99.0% at 6 months and 98.4% and 98.2% at 12 months as recorded in Thymoglobulin Antibody Immunosuppression in Living Donor Recipients registry and were 91.5% and 83.2% at 5 years by Kaplan-Meier estimates based on linked United Network for Organ Sharing registry records. Freedom from rejection was 93.6% through 5 years. Mean rATG cumulative dose was 5.29 mg/kg. More than one-third of patients (37.6%) were steroid-free at discharge, and nearly half of patients (48%) were steroid-free at 12 months. Before discharge, 3.2% experienced serious adverse events, with 11 events (0.005%) reported as possibly or probably related to rATG. Incidence of cytomegalovirus infection was 4.2% at 12 months, and 99.1% of patients were posttransplant lymphoproliferative disorder-free through 5 years. CONCLUSIONS: rATG induction in living donor renal transplantation is safe and associated with a low incidence of acute rejection and posttransplantation complications.

AB - BACKGROUND: The Thymoglobulin Antibody Immunosuppression in Living Donor Recipients registry was established to assess clinical experience with rabbit antithymocyte globulin (rATG; Thymoglobulin) in living donor renal transplant recipients. METHODS: From 2003 to 2008, US transplant centers prospectively entered information on patients who received rATG induction. In addition to standard United Network for Organ Sharing registry data elements, information was collected regarding immunosuppression, viral prophylaxis, acute rejection, and adverse events. RESULTS: Data on 2322 patients from 49 transplant centers were enrolled and met inclusion criteria for analysis. Patient and graft survival were 99.3% and 99.0% at 6 months and 98.4% and 98.2% at 12 months as recorded in Thymoglobulin Antibody Immunosuppression in Living Donor Recipients registry and were 91.5% and 83.2% at 5 years by Kaplan-Meier estimates based on linked United Network for Organ Sharing registry records. Freedom from rejection was 93.6% through 5 years. Mean rATG cumulative dose was 5.29 mg/kg. More than one-third of patients (37.6%) were steroid-free at discharge, and nearly half of patients (48%) were steroid-free at 12 months. Before discharge, 3.2% experienced serious adverse events, with 11 events (0.005%) reported as possibly or probably related to rATG. Incidence of cytomegalovirus infection was 4.2% at 12 months, and 99.1% of patients were posttransplant lymphoproliferative disorder-free through 5 years. CONCLUSIONS: rATG induction in living donor renal transplantation is safe and associated with a low incidence of acute rejection and posttransplantation complications.

KW - Antithymocyte globulin

KW - Immunosuppression

KW - Live donor transplantation

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=84865657975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865657975&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e31825a7d1f

DO - 10.1097/TP.0b013e31825a7d1f

M3 - Article

VL - 94

SP - 331

EP - 337

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 4

ER -